A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas.

被引：0
|
作者：
Furman, RR [1 ]
Sirulnik, A [1 ]
Kamalu, OO [1 ]
Brenner, RB [1 ]
Paciucci, PA [1 ]
Gabrilove, JL [1 ]
Waxman, S [1 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol & Oncol, New York, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4758
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [31] Paclitaxel/ifosfamide based regimens for the treatment of relapsed or refractory intermediate and high grade non-Hodgkin's lymphomas.
    Adler, SS
    Gregory, SA
    Venugopal, P
    O'Brien, T
    O'Donnell, K
    Woock, S
    BLOOD, 2001, 98 (11) : 238B - 238B
  • [32] High anti-lymphoma activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in rituximab pretreated relapsed or refractory indolent lymphomas. A multicentre phase II study of the german low grade lymphoma study group (GLSG).
    Weide, Rudolf
    Hess, Georg
    Koeppler, Hubert
    Heymanns, Jochen
    Thomalla, Joerg
    Aldaoud, Ali
    Losem, Christoph
    Schmitz, Stefan
    Haak, Ursula
    Huber, Christoph
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2006, 108 (11) : 702A - 703A
  • [33] FLUDARABINE SINGLE-AGENT THERAPY FOR RELAPSED LOW-GRADE NON-HODGKINS-LYMPHOMAS - A PHASE-II STUDY OF THE GERMAN LOW-GRADE NON-HODGKINS-LYMPHOMA STUDY-GROUP
    HIDDEMANN, W
    UNTERHALT, M
    POTT, C
    WORMANN, B
    SANDFORD, D
    FREUND, M
    ENGERT, A
    GASSMANN, W
    HOLTKAMP, W
    SEUFERT, J
    HELLRIEGEL, KP
    KNAUF, W
    EMMERICH, B
    KANZ, L
    KOCH, P
    SEMINARS IN ONCOLOGY, 1993, 20 (05) : 28 - 31
  • [34] Current treatment of follicular low-grade lymphomas
    Peterson, BA
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 2 - 11
  • [35] Overview of treatment of localized low-grade lymphomas
    MacManus, MP
    Hoppe, RT
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (05) : 901 - &
  • [36] EARLY OR LATE TREATMENT OF LOW-GRADE LYMPHOMAS
    PORTLOCK, CS
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 259 - 259
  • [37] Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas
    Girinsky, T
    Lapusan, S
    Ribrag, V
    Koscielny, S
    Ferme, C
    Carde, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02): : 476 - 479
  • [38] Phase II study of arsenic trioxide plus ascorbic acid for relapsed and refractory lymphoid malignancies: A Wisconsin Oncology Network Study.
    Kahl, BS
    Ahuja, HG
    Sanchez, FA
    Rodrigues, GA
    Voorhees, PM
    Stevens, EA
    Smith, J
    Turman, N
    Kim, KM
    Bailey, HH
    BLOOD, 2004, 104 (11) : 229B - 230B
  • [39] A phase II clinical study of arsenic trioxide (ATO) in patients(pts) with relapsed or refractory multiple myeloma (MM); a preliminary report
    Hussein, MA
    Mason, J
    Ravandi, F
    Rifkin, RM
    BLOOD, 2001, 98 (11) : 378A - 378A
  • [40] Arsenic trioxide (Trisenox®) in patients with relapsed or refractory multiple myeloma (MM):: Final report of a phase II clinical study.
    Hussein, MA
    Mason, J
    Saleh, MN
    Rifkin, RM
    Ravandi, F
    BLOOD, 2002, 100 (11) : 393B - 393B
12345